Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Aripiprazole — Abilify®

Brand: Abilify®
NICE TA: 213
Indication: Treatment of Schizophrenia in adults. Treatment of Schizophrenia in people aged 15 to 17 years (NICE TA213)
Disease category: Central nervous system
Commissioning responsibility: CCG
PbR excluded: No

Background

Recommended for the Treatment of Schizophrenia in adults by LMMG in line with Lancashire Care Foundation Trust formulary.

Recommended for the Treatment of Schizophrenia in people aged 15 to 17 years in line with NICE TA 213.

Recommendation

LMMG recommendation: Amber1
Click here to find the definitions for the colour classifications

Reason for decision:  The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Supporting documents:

NICE TA213 - Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

Antipsychotics Shared Care Guideline (Version 1.1) (340.0 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Amber 1

Amber1

Amber1

Amber1